Serum cetrorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction

Fertility and Sterility

Volumn 89, Issue 1, 2008, Pages 74-83

  Bukulmez, Orhan ^a,b   Carr, Bruce R ^b   Doody, Kathleen M ^a,b   Doody, Kevin J ^a,b  

^a Center for Assisted Reproduction   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

assisted reproduction; Cetrorelix acetate; clinical pregnancy; gonadotropin releasing hormone antagonist; implantation rate; in vitro fertilization; intracytoplasmic sperm injection; serum levels

Indexed keywords

CETRORELIX; ESTRADIOL;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; ESTRUS CYCLE; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PRIORITY JOURNAL;

ADULT; CHORIONIC GONADOTROPIN; EMBRYO IMPLANTATION; ESTRADIOL; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY; MALE; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 38049173335     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.02.017     Document Type: Article

References (62)

1. Albano C., Felberbaum R.E., Smitz J., Riethmuller-Winzen H., Engel J., Diedrich K., et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 15 (2000) 526-531
2. Borm G., and Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 15 (2000) 1490-1498
3. Fluker M., Grifo J., Leader A., Levy M., Meldrum D., Muasher S.J., et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75 (2001) 38-45
4. Blumenfeld Z. Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better?. Fertil Steril 76 (2001) 443-444
5. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16 (2001) 644-651
6. Al-Inany H., and Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 17 (2002) 874-885
7. Bukulmez O., Rehman K.S., Langley M., Carr B.R., Nackley A.C., Doody K.M., et al. Precycle administration of GnRH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation. Reprod Biomed Online 13 (2006) 465-475
8. Kol S. Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation?. Hum Reprod 15 (2000) 1881-1882
9. Oberye J.J., Mannaerts B.M., Huisman J.A., and Timmer C.J. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 72 (1999) 1006-1012
10. Gardner D.K., Schoolcraft W.B., Wagley L., Schlenker T., Stevens J., and Hesla J. A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. Hum Reprod 13 (1998) 3434-3440
11. Gardner D.K., Lane M., Stevens J., Schlenker T., and Schoolcraft W.B. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril 73 (2000) 1155-1158
12. Rehman KS, Bukulmez O, Langley M, Carr BR, Nackley AC, Doody KM, et al. Late stages of embryo progression are a much better predictor of clinical pregnancy than early cleavage in intracytoplasmic sperm injection and in vitro fertilization cycles with blastocyst-stage transfer. Fertil Steril. In press.
13. Franz A. Validation of an HPLC-MS/MS method for the determination of D-20761 in human plasma: prolytic GmbH; 2005 27 June 2005. Report No.: D-20761/050000001.
14. Al-Inany H. GnRH agonist versus antagonist therapy. Hum Reprod 17 (2002) 1413 author reply 1413-4
15. Arce J.C., Nyboe Andersen A., and Collins J. Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review. Hum Reprod 20 (2005) 1757-1771
16. Kolibianakis E.M., Collins J., Tarlatzis B.C., Devroey P., Diedrich K., and Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 12 (2006) 651-671
17. Al-Inany H.G., Abou-Setta A.M., and Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 3 (2006) CD001750
18. Muasher S.J., Abdallah R.T., and Hubayter Z.R. Optimal stimulation protocols for in vitro fertilization. Fertil Steril 86 (2006) 267-273
19. Tarlatzis B.C., Fauser B.C., Kolibianakis E.M., Diedrich K., and Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 12 (2006) 333-340
20. The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 13 (1998) 3023-3031
21. Prapas N., Prapas Y., Panagiotidis Y., Prapa S., Vanderzwalmen P., Schoysman R., et al. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Hum Reprod 20 (2005) 1516-1520
22. Seelig A.S., Al-Hasani S., Katalinic A., Schopper B., Sturm R., Diedrich K., et al. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 77 (2002) 472-475
23. Zikopoulos K., Kolibianakis E.M., Camus M., Tournaye H., Van den Abbeel E., Joris H., et al. Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertil Steril 81 (2004) 473-475
24. Medved R., Virant-Klun I., Meden-Vrtovec H., and Tomazevic T. Outcome of frozen-thawed blastocysts derived from gonadotropin releasing hormone agonist or antagonist cycles. J Assist Reprod Genet 23 (2006) 275-279
25. Mirkin S., Nikas G., Hsiu J.G., Diaz J., and Oehninger S. Gene expression profiles and structural/functional features of the peri-implantation endometrium in natural and gonadotropin-stimulated cycles. J Clin Endocrinol Metab 89 (2004) 5742-5752
26. Ruan H.C., Zhu X.M., Luo Q., Liu A.X., Qian Y.L., Zhou C.Y., et al. Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod 21 (2006) 2521-2529
27. Simon C., Oberye J., Bellver J., Vidal C., Bosch E., Horcajadas J.A., et al. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod 20 (2005) 3318-3327
28. Gustofson R.L., Segars J.H., and Larsen F.W. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod 21 (2006) 2830-2837
29. Hsueh A.J., and Erickson G.F. Extrapituitary action of gonadotropin-releasing hormone: direct inhibition ovarian steroidogenesis. Science 204 (1979) 854-855
30. Fraser H.M., Bramley T.A., Miller W.R., and Sharpe R.M. Extra pituitary actions of LHRH analogues in tissues of the human female and investigation of the existence and function of LHRH-like peptides. Prog Clin Biol Res 225 (1986) 29-54
31. Latouche J., Crumeyrolle-Arias M., Jordan D., Kopp N., Augendre-Ferrante B., Cedard L., et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125 (1989) 1739-1741
32. Billig H., Furuta I., and Hsueh A.J. Gonadotropin-releasing hormone directly induces apoptotic cell death in the rat ovary: biochemical and in situ detection of deoxyribonucleic acid fragmentation in granulosa cells. Endocrinology 134 (1994) 245-252
33. Billig H., Furuta I., and Hsueh A.J. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 133 (1993) 2204-2212
34. Chun S.Y., Billig H., Tilly J.L., Furuta I., Tsafriri A., and Hsueh A.J. Gonadotropin suppression of apoptosis in cultured preovulatory follicles: mediatory role of endogenous insulin-like growth factor I. Endocrinology 135 (1994) 1845-1853
35. Zhao S., Saito H., Wang X., Saito T., Kaneko T., and Hiroi M. Effects of gonadotropin-releasing hormone agonist on the incidence of apoptosis in porcine and human granulosa cells. Gynecol Obstet Invest 49 (2000) 52-56
36. Takekida S., Deguchi J., Samoto T., Matsuo H., and Maruo T. Comparative analysis of the effects of gonadotropin-releasing hormone agonist on the proliferative activity, apoptosis, and steroidogenesis in cultured porcine granulosa cells at varying stages of follicular growth. Endocrine 12 (2000) 61-67
37. Giampietro F., Sancilio S., Tiboni G.M., Rana R.A., and Di Pietro R. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist. Fertil Steril 85 (2006) 412-419
38. Garcia-Velasco J.A., Isaza V., Vidal C., Landazabal A., Remohi J., Simon C., et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 16 (2001) 2533-2539
39. Minaretzis D., Alper M.M., Oskowitz S.P., Lobel S.M., Mortola J.F., and Pavlou S.N. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am J Obstet Gynecol 172 (1995) 1518-1525
40. Minaretzis D., Jakubowski M., Mortola J.F., and Pavlou S.N. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 80 (1995) 430-434
41. Asimakopoulos B., Nikolettos N., Nehls B., Diedrich K., Al-Hasani S., and Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 86 (2006) 636-641
42. Edelstein M.C., Seltman H.J., Cox B.J., Robinson S.M., Shaw R.A., and Muasher S.J. Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. Fertil Steril 54 (1990) 853-857
43. Schoolcraft W., Sinton E., Schlenker T., Huynh D., Hamilton F., and Meldrum D.R. Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate. Fertil Steril 55 (1991) 563-566
44. Silverberg K.M., Burns W.N., Olive D.L., Riehl R.M., and Schenken R.S. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J Clin Endocrinol Metab 73 (1991) 797-803
45. Fanchin R., de Ziegler D., Taieb J., Hazout A., and Frydman R. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil Steril 59 (1993) 1090-1094
46. Givens C.R., Schriock E.D., Dandekar P.V., and Martin M.C. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles. Fertil Steril 62 (1994) 1011-1017
47. Ubaldi F., Smitz J., Wisanto A., Joris H., Schiettecatte J., Derde M.P., et al. Oocyte and embryo quality as well as pregnancy rate in intracytoplasmic sperm injection are not affected by high follicular phase serum progesterone. Hum Reprod 10 (1995) 3091-3096
48. Fanchin R., de Ziegler D., Castracane V.D., Taieb J., Olivennes F., and Frydman R. Physiopathology of premature progesterone elevation. Fertil Steril 64 (1995) 796-801
49. Shulman A., Ghetler Y., Beyth Y., and Ben-Nun I. The significance of an early (premature) rise of plasma progesterone in in vitro fertilization cycles induced by a "long protocol" of gonadotropin releasing hormone analogue and human menopausal gonadotropins. J Assist Reprod Genet 13 (1996) 207-211
50. Franchimont P., Hazee-Hagelstein M.T., Hazout A., Frydman R., Schatz B., and Demerle F. Correlation between follicular fluid content and the results of in vitro fertilization and embryo transfer. I. Sex steroids. Fertil Steril 52 (1989) 1006-1011
51. Legro R.S., Ary B.A., Paulson R.J., Stanczyk F.Z., and Sauer M.V. Premature luteinization as detected by elevated serum progesterone is associated with a higher pregnancy rate in donor oocyte in-vitro fertilization. Hum Reprod 8 (1993) 1506-1511
52. Check J.H., Hourani C., Choe J.K., Callan C., and Adelson H.G. Pregnancy rates in donors versus recipients according to the serum progesterone level at the time of human chorionic gonadotropin in a shared oocyte program. Fertil Steril 61 (1994) 262-264
53. Silverberg K.M., Martin M., Olive D.L., Burns W.N., and Schenken R.S. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration in in vitro fertilization cycles do not adversely affect embryo quality. Fertil Steril 61 (1994) 508-513
54. Chetkowski R.J., Kiltz R.J., and Salyer W.R. In premature luteinization, progesterone induces secretory transformation of the endometrium without impairment of embryo viability. Fertil Steril 68 (1997) 292-297
55. Hofmann G.E., Bergh P.A., Guzman I., Masuku S., and Navot D. Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle. Hum Reprod 8 (1993) 695-698
56. Bosch E., Valencia I., Escudero E., Crespo J., Simon C., Remohi J., et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 80 (2003) 1444-1449
57. Filicori M., Cognigni G.E., Pocognoli P., Tabarelli C., Ferlini F., Perri T., et al. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertil Steril 80 (2003) 390-397
58. Ubaldi F., Albano C., Peukert M., Riethmuller-Winzen H., Camus M., Smitz J., et al. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. Hum Reprod 11 (1996) 1405-1407
59. Ubaldi F., Camus M., Smitz J., Bennink H.C., Van Steirteghem A., and Devroey P. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH. Fertil Steril 66 (1996) 275-280
60. Filicori M., Cognigni G.E., Samara A., Melappioni S., Perri T., Cantelli B., et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 8 (2002) 543-557
61. Griesinger G., Schultze-Mosgau A., Dafopoulos K., Schroeder A., Schroer A., von Otte S., et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 20 (2005) 1200-1206
62. Cedrin-Durnerin I., Grange-Dujardin D., Laffy A., Parneix I., Massin N., Galey J., et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 19 (2004) 1979-1984